Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure

Peter G. Langley, Rick Keays, Robin D. Hughes, Alastair Forbes, Ullrich Delvos, Roger Williams – 1 August 1991 – Previous studies have shown that antithrombin III levels are low in fulminant hepatic failure, and heparin kinetics are abnormal, making control of heparinization difficult during hemodialysis of these patients who are at risk of bleeding.

Prognosis of unresectable hepatocellular carcinoma: An evaluation based on multivariate analysis of 90 cases

Yuka Akashi, Chizu Koreeda, Shigeki Enomoto, Shozo Uchiyama, Takako Mizuno, Yasuko Shiozaki, Yoshiko Sameshima, Kyoichi Inoue – 1 August 1991 – A multivariate analysis of data from 90 patients with unresectable hepatocellular carcinoma was performed using Cox's regression model to identify factors possibly affecting their prognoses. Thirty‐one patients underwent arterial anticancer chemotherapy, and the remaining 59 patients received transcatheter arterial embolization with anticancer agents.

Binding and internalization of transforming growth factor‐β1 by human hepatoma cells: Evidence for receptor recycling

Kim A. Sathre, Monica L.‐S. Tsang, James A. Weatherbee, Clifford J. Steer – 1 August 1991 – Cellular processing of 125I‐labeled transforming growth factor‐β1 was investigated in the human hepatoma cell lines Hep G2 and Hep 3B. Binding of 125I‐transforming growth factor‐β1 to cell surface receptors was specific, saturable and calciumindependent. Both cell lines exhibited a single class of high‐affinity (Kd = 2.2 × 10−10 mol/L) binding sites (4.5 × 103 for the Hep G2 cell; 1.5 × 103 for the Hep 3B cell) for both human and porcine transforming growth factor‐β1.

Identification of genetic differences in drug metabolism: Prediction of individual risk of toxicity or cancer

Daniel W. Nebert – 1 August 1991 – These two reports describe recombinant DNA tests that can identify individuals having a defect in the cytochrome P450IID6 (CYP2D6)‐mediated oxidative metabolism of debrisoquine and more than two dozen other drugs that are commonly prescribed. The poor metabolizer (PM), representing 5% to 10% of the northern European white population is homozygous for an autosomal recessive trait. Compared with the extensive metabolizer (EM) phenotype, the PM individual is more prone to toxicity caused by some of these drugs.

Replacement of cholesterol gallstones by murideoxycholyl taurine gallstones in prairie dogs fed murideoxycholic acid

Bertram I. Cohen, Nariman Ayyad, Erwin H. Mosbach, Charles K. McSherry, Naoyuki Matoba, Alan F. Hofmann, Huong‐Thu Ton‐Nu, Ying Peng, Claudio D. Schteingart, Richard J. Stenger – 1 July 1991 – The effect of two hydrophilic bile acids, murideoxycholic acid (3α,6β‐dihydroxy‐5β‐cholanoic acid) and ursodeoxycholic acid, on cholesterol and bile acid metabolism and hepatic pathology and gallstone composition was studied in the prairie dog. Cholesterol gallstones were induced by feeding a diet containing 1.2% cholesterol for 75 days.

Differences in the lectin‐binding patterns of the periportal and perivenous endothelial domains in the liver sinusoids

Emilio Barberá‐Guillem, Marian Rocha, Antonia Alvarez, Fernando Vidal‐Vanaclocha – 1 July 1991 – We have studied the distribution patterns of carbohydrate terminals on the endothelial surface of the mouse liver microvasculature. For this purpose, a wide battery of FITC lectins specific to glucose, mannose, galactose, fucose, N‐acetyl‐neuraminic acid, N‐acetylgalactosamine and N‐acetyl‐glucosamine residues were incubated on liver cryostat sections or intraportally perfused under physiological conditions.

Subscribe to